Travere Therapeutics
TVTX
59 hedge funds and large institutions have $186M invested in Travere Therapeutics in 2014 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 7 reducing their positions, and 12 closing their positions.
327% more call options, than puts
Call options by funds: $2.67M | Put options by funds: $625K
286% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 7
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
18% more funds holding
Funds holding: 50 → 59 (+9)
35% less capital invested
Capital invested by funds: $286M → $186M (-$100M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$16.7M |
| 2 |
LCM
LionEye Capital Management
New York
|
+$4.11M |
| 3 |
PA
Perceptive Advisors
New York
|
+$3.12M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.43M |
| 5 |
SAM
Senzar Asset Management
New York
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$6.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$4.19M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.77M |
| 4 |
Jane Street
New York
|
-$2.53M |
| 5 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$1.8M |
TVTX Hedge Fund Activity: Q2 2014 in Review
59 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2014, worth a combined $186M — down 35% from $286M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TVTX positions and 12 closed out — a net gain of 9 holders — while 27 added to existing stakes and 7 trimmed.
The largest buyer was Jennison Associates, adding an estimated $16.7M. The largest seller was Putnam Investments, cutting an estimated $6.4M.
- 59 institutional investors held Travere Therapeutics (TVTX) as of Q2 2014, up from 50 in Q1 2014.
- Funds reported $186M of Travere Therapeutics stock for Q2 2014, down 35% quarter-over-quarter.
- 21 funds opened new Travere Therapeutics positions in Q2 2014 and 12 closed out, a net change of +9 holders.
- The largest Travere Therapeutics buyer in Q2 2014 was Jennison Associates, an estimated $16.7M added.
- The largest Travere Therapeutics seller in Q2 2014 was Putnam Investments, an estimated $6.4M sold.
Based on aggregated 13F filings for Q2 2014.